Jihad S. Obeid

Dr. Jihad S. Obeid

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
JOJihad S. Obeid
Jihad S. Obeid
CMCatherine A. McGraw
Catherine A. McGraw
BMBrenda L. Minor
Brenda L. Minor
JCJose Conde
Jose Conde
RPRobert Pawluk
Robert Pawluk
PHPaul A. Harris
Paul A. Harris

19 August 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
GBGabriel A. Brat
Gabriel A. Brat
GWGriffin M. Weber
Griffin M. Weber
NGNils Gehlenborg
Nils Gehlenborg
PAPaul Avillach
Paul Avillach
NPNathan P. Palmer
Nathan P. Palmer
IKIsaac S. Kohane
Isaac S. Kohane
We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across five countries (www.covidclinical.net). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions.

1 April 2004 in Archives of Sexual Behavior
Verified
Journal Article
Closed access
PDF file
HMHeino F. L. Meyer-Bahlburg
Heino F. L. Meyer-Bahlburg
CDCurtis Dolezal
Curtis Dolezal
SBSusan W. Baker
Susan W. Baker
ACAnn D. Carlson
Ann D. Carlson
JOJihad S. Obeid
Jihad S. Obeid
MNMaria I. New
Maria I. New

1 April 2007 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
RWRobert C. Wilson
Robert C. Wilson
SNSaroj Nimkarn
Saroj Nimkarn
MDMiro Dumic
Miro Dumic
JOJihad S. Obeid
Jihad S. Obeid
MAMaryam Azar
Maryam Azar
MNMaria I. New
Maria I. New

1 October 1992 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
JOJihad S. Obeid
Jihad S. Obeid
PWPerrin C. White
Perrin C. White
Tyr-179 and Lys-183 are likely to be functionally important residues in 11 beta-hydroxysteroid dehydrogenase, as these amino acids are absolutely conserved in all members of the "short chain dehydrogenase" family. We modified these residues by site-directed mutagenesis of rat cDNA and transfected these constructs into CHO cells. A highly but not absolutely conserved residue, Asp-110, was also studied. Mutation of Tyr-179 to Phe or Ser completely abolished enzymatic activity (interconversion of corticosterone and 11-dehydrocorticosterone), as did Lys-183-->Arg. Asp-110-->Asn affected activity only mildly. Tyr-179 and Lys-183 may be directly involved in the catalytic function of this class of enzymes.

1 February 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
HMHeino F. L. Meyer-Bahlburg
Heino F. L. Meyer-Bahlburg
CDCurtis Dolezal
Curtis Dolezal
SBSusan W. Baker
Susan W. Baker
ACAnn D. Carlson
Ann D. Carlson
JOJihad S. Obeid
Jihad S. Obeid
MNMaria I. New
Maria I. New
Dexamethasone (DEX) administration to the pregnant woman has become the treatment of choice for the prevention of genital masculinization in female fetuses affected with congenital adrenal hyperplasia (CAH). Although no somatic teratological side effects have been found to date, recent animal research has shown adverse effects of glucocorticoids on brain structures such as the hippocampus, raising concerns about possible functional side effects of DEX on human development. The current survey of 487 children, 1 month to 12 yr of age, focused on cognitive and motor development. The mothers of 174 prenatally DEX-exposed children (including 48 with CAH) and 313 unexposed children (including 195 with CAH) completed four standardized developmental questionnaires about their children. None of the comparisons of prenatally DEX-exposed children and unexposed controls was significant. Among the DEX-exposed children, increased duration of DEX exposure was correlated with significantly fewer developmental delays on three variables of one of the questionnaires, but none of the correlations reached significance, when Bonferroni corrections for multiple correlations were used. With the methods used, we were unable to document any adverse effects of early-prenatal DEX treatment in the doses recommended for the treatment of pregnancies at risk for CAH on motor and cognitive development.